Stockscreener 앱 받기
20.42
0.20%
-0.04
시간 외 거래:
20.42
전일 마감가:
$20.46
열려 있는:
$20.16
하루 거래량:
1.65M
Relative Volume:
0.61
시가총액:
$1.97B
수익:
$672.72M
순이익/손실:
$-575.44M
주가수익비율:
-3.4989
EPS:
-5.8361
순현금흐름:
$-487.00M
1주 성능:
-5.94%
1개월 성능:
-6.46%
6개월 성능:
-27.41%
1년 성능:
-48.54%
1일 변동 폭
$19.90
$20.57
1주일 범위
$19.90
$22.27
52주 변동 폭
$18.41
$42.37
울트라제닉스 파마슈티컬 Stock (RARE) Company Profile
명칭
Ultragenyx Pharmaceutical Inc
전화
415-483-8800
주소
60 LEVERONI COURT, NOVATO, CA
Compare RARE vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
20.42 | 1.98B | 672.72M | -575.44M | -487.00M | -5.8361 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
울트라제닉스 파마슈티컬 Stock (RARE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-20 | 개시 | Wells Fargo | Overweight |
| 2025-07-28 | 재개 | H.C. Wainwright | Buy |
| 2025-05-28 | 개시 | William Blair | Outperform |
| 2024-06-06 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-04-22 | 개시 | RBC Capital Mkts | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-06-14 | 재개 | Credit Suisse | Outperform |
| 2023-06-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-04-26 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-01-18 | 재개 | Canaccord Genuity | Buy |
| 2022-12-30 | 재개 | H.C. Wainwright | Buy |
| 2022-11-03 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-08-01 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-03-16 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-09-30 | 개시 | H.C. Wainwright | Buy |
| 2021-08-19 | 개시 | UBS | Sell |
| 2021-07-15 | 개시 | Guggenheim | Neutral |
| 2021-06-29 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Neutral |
| 2021-05-06 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-05-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Neutral |
| 2021-03-02 | 재개 | Stifel | Buy |
| 2021-02-12 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-12-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2020-11-24 | 재개 | Evercore ISI | In-line |
| 2020-11-12 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2019-08-02 | 재개 | Wedbush | Outperform |
| 2019-03-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | 재개 | Raymond James | Outperform |
| 2019-01-02 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | 업그레이드 | Citigroup | Sell → Neutral |
| 2018-09-10 | 개시 | Morgan Stanley | Equal-Weight |
| 2018-06-21 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2018-05-10 | 개시 | Goldman | Neutral |
| 2018-04-18 | 업그레이드 | SunTrust | Hold → Buy |
| 2018-03-22 | 재개 | Piper Jaffray | Overweight |
| 2018-02-21 | 재확인 | Stifel | Buy |
| 2018-01-22 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2018-01-18 | 개시 | Credit Suisse | Outperform |
| 2017-12-05 | 재확인 | Barclays | Equal Weight |
| 2017-12-04 | 업그레이드 | Jefferies | Hold → Buy |
| 2017-09-14 | 업그레이드 | Wedbush | Neutral → Outperform |
모두보기
울트라제닉스 파마슈티컬 주식(RARE)의 최신 뉴스
INVESTOR DEADLINE: Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action LawsuitRGRD Law - ChartMill
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors - GlobeNewswire
RARE DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. ... - Caledonian Record
התראת מועד אחרון לתביעה נגד RARE: רוזן, יועץ למשקיעים מיומן, מעודד משקיעים ב-Ultragenyx Pharmaceutical Inc עם הפסדים של יותר מ-100 אלף דולר לקבל ייעוץ משפטי לפני מועד אחרון חשוב בתביעה ייצוגית לניירות ערך – RARE - GlobeNewswire Inc.
RARE CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) ... - Bluefield Daily Telegraph
Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx - GlobeNewswire
LEVI & KORSINSKY, LLP: FRAUD-ON-THE-MARKET DOCTRINE UNDERPINS ULTRAGENYX PHARMACEUTICAL SECURITIES CLASS ACTION - PR Newswire
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 - GlobeNewswire
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - GlobeNewswire Inc.
INVESTOR DEADLINE: Ultragenyx Pharmaceutical Inc. Investors - GlobeNewswire
DTX301 Gene Therapy Lowers Ammonia Levels in Ornithine Transcarbamylase Deficiency at 36 Weeks - Neurology Live
RARE Shareholder Alert: Ultragenyx Pharmaceutical Inc. Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm - PR Newswire
Aquatic Capital Management LLC Increases Holdings in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
RARE INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 - PR Newswire
Portnoy Law Firm Announces Class Action on Behalf of Ultragenyx Pharmaceutical, Inc. Investors - GlobeNewswire
ULTRAGENYX PHARMACEUTICAL INC. SECURITIES FRAUD NOTICE: Berger Montague Informs Ultragenyx Pharmaceutical Inc. (RARE) Investors of a Securities Fraud Lawsuit - marketscreener.com
Farallon Capital Management LLC Decreases Stock Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
First Light Asset Management LLC Trims Holdings in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Algert Global LLC Purchases 205,286 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Rosen Law Firm Encourages Ultragenyx Investors to Secure Counsel Before Deadline - National Today
ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
ROSEN, TRUSTED AND TOP RANKED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionRARE - ACCESS Newswire
Braidwell LP Acquires New Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Holzer & Holzer, LLC Reminds Investors of April 6, 2026 Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against BlackRock TCP Capital Corp. (TCPC), Mereo BioPharma Group plc (MREO), POMDOCTOR LIMITED (POM), and Ultragenyx Phar - marketscreener.com
Suvretta Capital Management LLC Decreases Stock Holdings in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx EVP Pinion sells $228k in shares By Investing.com - Investing.com Nigeria
Ultragenyx’s gene therapy meets co-primary endpoint in Phase III trial - Yahoo
DEADLINE: Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit – Company AnnouncementFT.com - Financial Times
RARE DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 (2026-03-13) - Seeking Alpha
RARE Shareholder Alert: Ultragenyx Pharmaceutical Inc. Securities Class Action Lawsuit ... - Bluefield Daily Telegraph
RARE Shareholder Alert: Ultragenyx Pharmaceutical Inc. - GlobeNewswire
RARE's DTX301 Meets First Key Goal in Phase III OTC Deficiency Study - Yahoo Finance
Ultragenyx reveals positive Phase III results for DTX301 AAV8 gene therapy - The Pharma Letter
Russell Investments Group Ltd. Increases Holdings in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
DEADLINE: Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit - Sahm
Ultragenyx reports positive Phase 3 data for OTC gene therapy By Investing.com - Investing.com India
Ultragenyx's Gene Therapy Study Shows Ammonia Reduction In Rare Metabolic Disorder - Sahm
Bank of America, Leerink Maintain Buy/Outperform on RARE Ultragenyx March 2026 - Meyka
Ultragenyx reports positive Phase 3 data for OTC gene therapy - Investing.com South Africa
JP Morgan Lowers Price Target for Ultragenyx Pharmaceutical (RAR - GuruFocus
ROSEN, A LEADING LAW FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure ... - Bluefield Daily Telegraph
ROSEN, A LEADING LAW FIRM, Encourages Ultragenyx - GlobeNewswire
Ultragenyx Pharmaceutical (NASDAQ:RARE) Given New $74.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Leerink Partners reiterates Ultragenyx stock rating on trial data - Investing.com Nigeria
Ultragenyx Pharmaceutical Inc Announces Positive 36-Week Data From Phase 3 Study Of DTX301 AAV8 Gene Therapy For The Treatment Of Ornithine Transcarbamylase Deficiency - marketscreener.com
BofA reiterates Ultragenyx stock rating on positive gene therapy data - Investing.com
Leerink Partners reiterates Ultragenyx stock rating on trial data By Investing.com - Investing.com India
Ultragenyx gene therapy posts Phase III win for urea cycle disorder - FirstWord Pharma
Ultragenyx posts late-stage trial win for gene therapy in urea cycle disorder - Seeking Alpha
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming DeadlinesRARE - PR Newswire
Ultragenyx Announces Positive Phase 3 Results for DTX301 - TipRanks
울트라제닉스 파마슈티컬 (RARE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):